Full Text View
Tabular View
No Study Results Posted
Related Studies
Hyperbaric Oxygen Therapy Compared With Standard Therapy in Treating Chronic Arm Lymphedema in Patients Who Have Undergone Radiation Therapy for Cancer
This study is ongoing, but not recruiting participants.
Study NCT00077090   Information provided by National Cancer Institute (NCI)
First Received: February 10, 2004   Last Updated: May 9, 2009   History of Changes
This Tabular View shows the required WHO registration data elements as marked by

February 10, 2004
May 9, 2009
April 2004
Volume of the affected limb, expressed as a percentage of the contralateral limb Volume on the day of measurement, as measured by perometer 12 months after baseline assessment
Same as current
Complete list of historical versions of study NCT00077090 on ClinicalTrials.gov Archive Site
  • Patient self-assessments, using specific quality of life scale in upper limb lymphoedema and the UK SF-36 Health Survey Questionnaire, at 3, 6, 9 and 12 months after baseline assessment
  • 99Tc-nanocolloid clearance rate as measured by quantitative lymphoscintigraphy 12 months after baseline assessment
  • Extracellular water content as measured by EdemaMeter (bioimpedance measurements) 12 months after baseline assessment
  • Patient self-assessments, using specific quality of life scale in upper limb lymphoedema and the UK SF-36 Health Survey Questionnaire, at 3, 6, 9 and 12 months after baseline assessment
  • 99Tc-nanocolloid clearance rate as measured by quantitative lymphoscintigraphy 12 months after baseline assessment
  • Extracellular water content as measured by EdemaMeter (bioimpedance measurements) 12 months after baseline assessment
 
Hyperbaric Oxygen Therapy Compared With Standard Therapy in Treating Chronic Arm Lymphedema in Patients Who Have Undergone Radiation Therapy for Cancer
Randomized Phase II Trial Of Hyperbaric Oxygen Therapy In Patients With Chronic Arm Lymphoedema After Radiotherapy For Cancer

RATIONALE: Hyperbaric oxygen therapy may be effective in repairing damaged tissue and reducing lymphedema caused by radiation therapy for cancer.

PURPOSE: This randomized phase II trial is studying hyperbaric oxygen to see how well it works compared to standard therapy in treating chronic arm lymphedema in patients who have undergone radiation therapy for cancer.

OBJECTIVES:

Primary

  • Compare the efficacy of hyperbaric oxygen (HBO) therapy vs standard management, in terms of reduction of lymphedema, in patients with chronic arm lymphedema after radiotherapy for cancer.

Secondary

  • Determine the mechanisms of tissue reperfusion and healing in patients treated with HBO therapy.

OUTLINE: This is a randomized study. Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients undergo hyperbaric oxygen therapy over 90 minutes 5 days a week for 6 weeks.
  • Arm II: Patients receive standard management. Patients are followed at 3, 6, 9, 12, and 15 months.

Peer Reviewed and Funded or Endorsed by Cancer Research UK

PROJECTED ACCRUAL: A total of 63 patients (42 for arm I and 21 for arm II) will be accrued for this study.

Phase II
Interventional
Supportive Care, Randomized, Active Control
  • Breast Cancer
  • Lymphedema
  • Perioperative/Postoperative Complications
  • Radiation Fibrosis
Drug: hyperbaric oxygen
 
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Active, not recruiting
63
 
 

DISEASE CHARACTERISTICS:

  • History of early breast cancer (T1-3, N0-1, M0)
  • Prior breast surgery with or without axillary dissection
  • Prior breast/chest wall radiotherapy with or without radiotherapy to the supraclavicular fossa and/or axilla, completed at least 2 years ago
  • Arm lymphedema

    • At least 15% increase in arm volume
  • No evidence of cancer recurrence
  • Hormone receptor status:

    • Not specified

PATIENT CHARACTERISTICS:

Age

  • Over 18

Sex

  • Female or male

Menopausal status

  • Not specified

Performance status

  • Not specified

Life expectancy

  • Not specified

Hematopoietic

  • Not specified

Hepatic

  • Not specified

Renal

  • Not specified

Pulmonary

  • No chronic obstructive airway disease
  • No bullous lung disease
  • No acute or chronic pulmonary infection
  • No uncontrolled asthma
  • No untreated pneumothorax

Other

  • Physically and psychologically fit for HBO therapy
  • No claustrophobia
  • No epilepsy
  • No eustachian tube dysfunction
  • No recurrent attacks of vertigo
  • No contraindication to MRI (e.g., intracranial ferrous material)

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • Not specified

Chemotherapy

  • Not specified

Endocrine therapy

  • Not specified

Radiotherapy

  • See Disease Characteristics

Surgery

  • See Disease Characteristics
  • No prior ear operations

Other

  • No prior hyperbaric oxygen (HBO) therapy, except as treatment for decompression illness
Both
18 Years and older
No
 
United Kingdom
 
 
NCT00077090
 
RMNHS-HOT, EU-20337
Institute of Cancer Research, United Kingdom
 
Study Chair: John R. Yarnold, MD, FRCR Royal Marsden - Surrey
National Cancer Institute (NCI)
September 2007

 †    Required WHO trial registration data element.
††   WHO trial registration data element that is required only if it exists.